Helix BioPharma Corp. presented new data on its CEACAM6-directed antibody-drug conjugate program at the 16th Annual World ADC London conference. The presentation, delivered by Director of ADC Discovery Jonathan Davis, PhD, focused on the development of next-generation ADCs targeting CEACAM6, a protein highly expressed in various epithelial cancers.
The conference, now in its 16th year, represents one of the leading global forums dedicated to ADC research and development, bringing together more than 700 industry stakeholders from over 240 companies. Davis's participation in the Seminar Day program underscores Helix's growing leadership in innovative ADC technologies. The presentation highlighted CEACAM6 as a compelling therapeutic target due to its elevated expression across multiple cancers, association with poor clinical outcomes, and limited expression in healthy tissues.
Davis presented data supporting the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies. This nanobody demonstrated preferential binding to tumor-expressed CEACAM6, supporting the development of ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects. The approach builds on the clinical foundation established by Helix's lead candidate, Tumor Defense Breaker™ L-DOS47, which has shown favorable safety and encouraging clinical activity in Phase I/II studies for non-small cell lung cancer.
"CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers," said Davis. "Our proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects." The presentation generated strong interest among conference participants, reflecting growing recognition of CEACAM6 as an important emerging target in oncology.
The implications of this research extend across the oncology landscape, particularly for patients with cancers that have limited treatment options. By targeting CEACAM6 with highly selective ADCs, Helix aims to develop therapies that could improve outcomes for multiple cancer types while reducing treatment-related side effects. The company's approach represents a significant advancement in targeted cancer therapy, potentially offering new treatment paradigms for epithelial cancers that currently have poor prognoses.
A copy of the presentation is available on the Company's website at https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf. The World ADC London conference continues to serve as a critical platform for scientific exchange in ADC development, with more information available at https://worldadc-europe.com/. Helix BioPharma maintains its corporate information at https://www.helixbiopharma.com/.
